This morning, Aquestive Therapeutics supplied a pivotal regulatory replace relating to its lead product candidate, Anaphylm™ Sublingual Movie, a needle-free therapy for extreme allergic reactions. On January 9, 2026, the corporate introduced it had obtained a letter from the US Meals and Drug Administration (FDA) indicating that the company had recognized “deficiencies” within the New Drug Software (NDA). These points are at present stopping the initiation of labeling discussions or the finalization of post-marketing commitments, that are sometimes the ultimate steps earlier than a possible approval.
Regardless of the setback, the FDA confirmed that its evaluation of the Anaphylm NDA stays energetic and that no ultimate resolution has been made on the drug’s approvability. The company’s notification didn’t specify the precise nature of the deficiencies, but it surely clarified that the letter doesn’t represent a ultimate regulatory motion. The corporate stays targeted on its Prescription Drug Person Price Act (PDUFA) goal motion date, at present set for January 31, 2026.
Dan Barber, President and Chief Government Officer of Aquestive, addressed the event with a give attention to cooperation and transparency. “As a part of its ongoing evaluation of the Firm’s NDA for Anaphylm, the FDA notified us that it had recognized deficiencies within the NDA that preclude dialogue of labeling and post-marketing commitments at the moment,” Barber acknowledged. He added, “We stay dedicated to working carefully with the FDA to deal with any excellent gadgets as we transfer towards the January 31, 2026, PDUFA purpose date.”
Whereas the home path faces new hurdles, Aquestive is aggressively pursuing worldwide growth for Anaphylm. The corporate reported vital progress in world markets, together with ongoing regulatory actions in Canada, the European Union, and the UK. This technique goals to offer a device-free, sublingual different to conventional epinephrine auto-injectors on a worldwide scale, tapping into a major unmet want for extra moveable and fewer invasive emergency allergy therapies.
Finally, the announcement highlights the volatility of the biotech regulatory panorama. Whereas the “deficiencies” recognized by the FDA introduce uncertainty, Aquestive’s management maintains a constructive outlook on the transformative potential of their sublingual movie expertise. Because the January PDUFA date approaches, the meals allergy group might be watching carefully to see how shortly the corporate can resolve the company’s considerations and produce the primary non-invasive epinephrine movie to market.
